Janki Bodiwala's 'Vash Level 2' has captivated audiences, grossing Rs 8.59 crore in its first week. Directed by Krishnadev Yagnik, the film benefits from strong weekend showings and positive ...

Gujarati horror film 'Vash Level 2' released on August 27. The film coincided with Ganesh Chaturthi. It had a strong opening at the domestic box office. The film earned around Rs.1.50–1.75 crore ...

Crosswords & Games Word Flower: Level 2 How many words can you come up with on today’s Word Flower: Level 2 challenge? Try to complete today’s game or play past puzzles you missed. NJ surgeon who ...

“It can replenish a lot of power in my electric car in a short time.” Autoblog aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission.

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. This article has ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

In Vash Level 2, Gujarati writer-director Krishnadev Yagnik is back on territory he visited in his 2023 hit Vash: demonic possession. Vash, which was remade in Hindi in 2024 as Shaitaan, explores the ...

Maruti Suzuki India Limited (MSIL) has revealed the Victoris, its first car equipped with Level-2 Advanced Driver Assistance Systems (ADAS). Positioned above the Brezza, the Victoris becomes the new ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 5, Needham reiterated its Buy rating on Recursion Pharmaceuticals, Inc.

As well as boosting its GeForce Now cloud streaming with PS5 Pro-beating hardware and new peripheral options, Nvidia has also detailed some of its recent RTX Remix successes at Gamescom 2025. If ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 ...